Geron Corporation (GERN) News
Follow Geron Corporation (GERN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 24 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Geron Reports Results for Quarter Ended September 30
EARNINGS | Nov 04, 2026, 03:12 PM UTC
M
Geron Q3 Revenue Rises to $60.1 Million; Net Income Reaches $1.4 Million
Third-quarter product revenue increased from $47.2 million a year earlier. Operating income was $5.8 million, versus an operating loss in the prior-year quarter; Geron maintained its 2026 RYTELO revenue outlook.
EQUITY | Nov 04, 2026, 12:33 PM UTC
M
Geron Swings to Q3 2026 Net Profit of $1.35 Million
Geron reported a $1.35 million net profit in Q3 2026, compared with a loss a year earlier.
EQUITY | Nov 04, 2026, 12:19 PM UTC
M
Geron Reports Third-Quarter Revenue of $60.2M
EQUITY | Nov 04, 2026, 12:12 PM UTC
M
Geron Reports Q3 2026 Results and Business Highlights
Geron reported $60.1 million in RYTELO net product revenue in Q3 2026, up 5%.
EQUITY | Nov 04, 2026, 12:05 PM UTC
M
Geron to Discontinue Phase 3 Imetelstat Trial in Myelofibrosis
Geron disclosed in an SEC filing that it will discontinue the Phase 3 IMpactMF trial of imetelstat in myelofibrosis.
EQUITY | Oct 28, 2026, 08:53 PM UTC
M
Geron halts late-stage blood cancer drug trial; shares plunge
Geron halted a late-stage trial of a blood cancer drug, and its shares plunged.
EQUITY | Oct 28, 2026, 03:10 PM UTC
L
Geron Shares Fall After Late-Stage Cancer Study Is Halted
Geron shares fell after a late-stage cancer study was halted.
EQUITY | Oct 28, 2026, 01:40 PM UTC
M
Geron halts late-stage trial of blood cancer treatment
EQUITY | Oct 28, 2026, 01:36 PM UTC
M
Geron Suspends Late-Stage Trial of Blood Cancer Drug
Geron suspended a late-stage trial of a drug for blood cancer.
EQUITY | Oct 28, 2026, 01:09 PM UTC
M
Geron Ends Phase 3 Rytelo Study in Myelofibrosis for Futility
Geron said an independent data monitoring committee advised ending the late-stage study because it was likely to fail.
EQUITY | Oct 28, 2026, 12:20 PM UTC
M
Geron halts Phase 3 imetelstat study in myelofibrosis
Geron said it halted its Phase 3 study of imetelstat in myelofibrosis.
EQUITY | Oct 28, 2026, 12:12 PM UTC
M
Geron Discontinues Phase 3 Myelofibrosis Trial
Geron announced a decision to discontinue the Phase 3 IMpactMF trial evaluating imetelstat in relapsed/refractory myelofibrosis.
EQUITY | Oct 28, 2026, 12:12 PM UTC
M
Geron halts late-stage blood cancer drug trial
Geron said it will discontinue a late-stage trial of a treatment for patients with a type of rare blood cancer.
EQUITY | Oct 28, 2026, 12:08 PM UTC
M
Geron Halts Late-Stage Blood Cancer Drug Study
Geron has halted a late-stage study of a drug for blood cancer, Reuters reports.
EQUITY | Oct 28, 2026, 12:07 PM UTC
M
Nasdaq halts trading pending news at 7:55 a.m.
EQUITY | Oct 28, 2026, 11:55 AM UTC
H
Geron Q2 2026 Earnings Call: Complete Transcript
Geron (NASDAQ: GERN ) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you APIs. For real-time access to our entire catalog, ple
LIVE | Oct 08, 2026, 08:19 AM UTC
L
GERN - Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GERN - Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWS | Sep 18, 2026, 08:01 PM UTC
L
Geron raises revenue guidance to $230–$240 million
Geron raised revenue guidance to $230—$240 million, citing strong growth. The company also said profitability is in sight, while it expands into deeper community penetration and international markets and advances a pivot
EARNINGS | Sep 09, 2026, 02:06 PM UTC
M
Geron says disciplined spending supports revenue growth and profitability path
Geron reports revenue up 24% year-to-date, citing disciplined spending and deeper community penetration, plus earlier-line patient use. International expansion and a myelofibrosis trial are flagged as near-term prioritie
EQUITY | Sep 09, 2026, 01:39 PM UTC
L
Geron management set for upcoming investor conferences
Geron Corporation said members of its management team are scheduled to participate in upcoming investor conferences, according to the company announcement.
EQUITY | Sep 02, 2026, 12:07 PM UTC
L
GERN - Geron to Present at Upcoming Investor Conferences
GERN - Geron to Present at Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 12:02 PM UTC
L
Geron (GERN) reports inducement grants under Nasdaq Rule 5635(c)(4)
Geron Corporation reports inducement grants under Nasdaq Listing Rule 5635(c)(4).
REGULATION | Aug 18, 2026, 08:01 PM UTC
L
GERN - Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights
GERN - Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights
EARNINGS | Aug 05, 2026, 11:01 AM UTC